

# UPDATES ON APPROACHES TO ACCEPTABLE INTAKES OF NITROSAMINE DRUG SUBSTANCE RELATED IMPURITIES (NDSRIS) AND BIOEQUIVALENCE ASSESSMENT FOR REFORMULATED DRUG PRODUCTS

## Day 2 Session 2B: NDSRIs: Risk Factors of Formation, Confirmatory Testing, and Risk Mitigation

<i>Introductions:</i>	<b>Andre Raw, PhD</b> <b>Dan Snider, PhD</b>	Associate Director, Science and Communication, OPQA I, OPQ, FDA Head of Global Quality Compliance, Viatris
<i>Presenters:</i>	<b>Naiffer Romero, MSc, MPH</b> <b>Guozhang Zou, PhD</b> <b>Jingyue (Jan) Yang, PhD</b> <b>Xiang Yu, PhD</b> <b>Nitish Sharma, PhD</b>	Principal Scientist, Science Division, United State Pharmacopeia Research Scientist, DPQR V, OPQ, FDA Senior Research Scientist, DPQR I, OPQR, OPQ, FDA Senior Biologist, OPQA I, OPQ, FDA Assistant Professor, Dept of Pharmaceutical Analysis, NIPER-Ahmedabad
<i>Moderator:</i>	<b>Andre Raw, PhD</b> <b>Dan Snider, PhD</b>	Associate Director, Science and Communication, OPQA I, OPQ, FDA Head of Global Quality Compliance, Viatris
<i>Panelists:</i>	<b>Naiffer Romero, MSc, MPH</b> <b>Guozhang Zou, PhD</b> <b>Jingyue (Jan) Yang, PhD</b> <b>Xiang Yu, PhD</b> <b>Nitish Sharma, PhD</b>	Principal Scientist, Science Division, United State Pharmacopeia Research Scientist, DPQR V, OPQ, FDA Senior Research Scientist, DPQR I, OPQR, OPQ, FDA Senior Biologist, OPQA I, OPQ, FDA Assistant Professor, Dept of Pharmaceutical Analysis, NIPER-Ahmedabad